CN118984821A - 作为apol1抑制剂的2-甲基-4-苯基哌啶-4-醇衍生物和其使用方法 - Google Patents
作为apol1抑制剂的2-甲基-4-苯基哌啶-4-醇衍生物和其使用方法 Download PDFInfo
- Publication number
- CN118984821A CN118984821A CN202380032016.8A CN202380032016A CN118984821A CN 118984821 A CN118984821 A CN 118984821A CN 202380032016 A CN202380032016 A CN 202380032016A CN 118984821 A CN118984821 A CN 118984821A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- groups
- optionally substituted
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263307933P | 2022-02-08 | 2022-02-08 | |
| US63/307933 | 2022-02-08 | ||
| PCT/US2023/012579 WO2023154310A1 (en) | 2022-02-08 | 2023-02-08 | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118984821A true CN118984821A (zh) | 2024-11-19 |
Family
ID=85570218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380032016.8A Pending CN118984821A (zh) | 2022-02-08 | 2023-02-08 | 作为apol1抑制剂的2-甲基-4-苯基哌啶-4-醇衍生物和其使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250163021A1 (https=) |
| EP (1) | EP4476199A1 (https=) |
| JP (1) | JP2025505200A (https=) |
| CN (1) | CN118984821A (https=) |
| AU (1) | AU2023219516A1 (https=) |
| CA (1) | CA3251230A1 (https=) |
| WO (1) | WO2023154310A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039676A (en) * | 1975-06-23 | 1977-08-02 | Ciba-Geigy Corporation | 2-piperidinoalkyl-1,4-benzodioxans |
| US6518423B1 (en) * | 1996-08-09 | 2003-02-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
| AR048523A1 (es) * | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
| JP5406722B2 (ja) * | 2006-10-16 | 2014-02-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体 |
| BR102012024778A2 (pt) * | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
| CN106749330A (zh) * | 2016-12-29 | 2017-05-31 | 长春海谱润斯科技有限公司 | 一种杂环衍生物及使用该杂环衍生物的有机发光器件 |
| US20220144838A1 (en) * | 2019-03-13 | 2022-05-12 | Nanjing Immunophage Biotech Co., Ltd. | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor |
| IL296423A (en) * | 2020-04-22 | 2022-11-01 | Anima Biotech Inc | Collagen 1 translation inhibitors and methods of use thereof |
| CN115867532A (zh) * | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
-
2023
- 2023-02-08 AU AU2023219516A patent/AU2023219516A1/en active Pending
- 2023-02-08 EP EP23710516.8A patent/EP4476199A1/en active Pending
- 2023-02-08 CA CA3251230A patent/CA3251230A1/en active Pending
- 2023-02-08 JP JP2024546424A patent/JP2025505200A/ja active Pending
- 2023-02-08 CN CN202380032016.8A patent/CN118984821A/zh active Pending
- 2023-02-08 WO PCT/US2023/012579 patent/WO2023154310A1/en not_active Ceased
- 2023-02-08 US US18/836,463 patent/US20250163021A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025505200A (ja) | 2025-02-21 |
| AU2023219516A1 (en) | 2024-08-22 |
| CA3251230A1 (en) | 2023-08-17 |
| US20250163021A1 (en) | 2025-05-22 |
| EP4476199A1 (en) | 2024-12-18 |
| WO2023154310A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118984821A (zh) | 作为apol1抑制剂的2-甲基-4-苯基哌啶-4-醇衍生物和其使用方法 | |
| EP3788039B1 (en) | Factor xiia inhibitors | |
| CN110352188B (zh) | 氟代烯丙胺衍生物及其用途 | |
| CN104411701B (zh) | 作为Bub1抑制剂的用于治疗癌症的取代的环烯并吡唑 | |
| CN105143201B (zh) | 苄胺衍生物 | |
| BR112017016193B1 (pt) | Derivados de 4h-pirrolo[3,2-c]piridin-4-ona | |
| CN105452236A (zh) | 取代的苄基吡唑 | |
| PH12014502573B1 (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| US12612379B2 (en) | Inhibitors of APOL1 and methods of using same | |
| CA3240523A1 (en) | Spirocyclic inhibitors of apol1 and methods of using same | |
| JP2025505644A (ja) | Ａｐｏｌ１の阻害剤としての４’，５’－ジヒドロスピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、及びそれを使用する方法 | |
| EP2513094B1 (en) | Crystalline salts of a factor xa inhibitor | |
| JP3116256B2 (ja) | （チオ）ウレア誘導体 | |
| EP0577218A1 (en) | Heterocyclyl-phenoxyalkyl-piperidinylpyridazines as antiviral agents | |
| US20110160250A1 (en) | Crystalline forms of a factor xa inhibitor | |
| HK40048874A (en) | Factor xiia inhibitors | |
| HK40048874B (en) | Factor xiia inhibitors | |
| HK1177459B (en) | Crystalline salts of a factor xa inhibitor | |
| WO2016146605A1 (de) | Substituierte phenylalanin-derivate | |
| CN105878243A (zh) | 吡非尼酮衍生物在制药中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |